Expert Review of Molecular Diagnostics最新文献_第5页

Role of liquid biopsy in genitourinary (GU) cancers. 液体活检在泌尿生殖系统癌中的作用。

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-06-01 Epub Date: 2026-05-17 DOI: 10.1080/14737159.2026.2673947

Mehmet Kayaalp, Emre Yekedüz, Yüksel Ürün

{"title":"Role of liquid biopsy in genitourinary (GU) cancers.","authors":"Mehmet Kayaalp, Emre Yekedüz, Yüksel Ürün","doi":"10.1080/14737159.2026.2673947","DOIUrl":"10.1080/14737159.2026.2673947","url":null,"abstract":"Introduction: Liquid biopsy is a noninvasive diagnostic and monitoring method that provides molecular information about disease by analyzing tumor-derived biomaterials obtained from body fluids-primarily blood, as well as plasma, urine, saliva, and others-including circulating tumor DNA (ctDNA), RNA, circulating tumor cells, and exosomes. Consequently, liquid biopsy has become one of the most intensely investigated and rapidly evolving fields in contemporary oncology.Areas covered: This narrative review covers the molecular components and isolation techniques underlying liquid biopsy platforms, and examines their clinical applications across prostate cancer, bladder cancer, renal cell carcinoma, and testicular germ cell tumors, encompassing pre-biopsy risk stratification, treatment-response monitoring, detection of resistance mechanisms, and minimal residual disease surveillance.Expert opinion: Clinical utility is now the main barrier to routine adoption of liquid biopsy in genitourinary cancers. Prospective studies must demonstrate that liquid biopsy-guided strategies, including biopsy avoidance, perioperative MRD driven escalation or de-escalation, and adaptation of therapy in the metastatic setting, improve clinically meaningful outcomes and are cost-effective. Standardized pre-analytical procedures, harmonized reporting thresholds, and clear management algorithms for discordant results will be essential for reliable real world implementation.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"461-481"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147927937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic accuracy of fine-needle aspiration cytology in salivary gland neoplasms: a systematic review and meta-analysis. 细针穿刺细胞学在唾液腺肿瘤诊断中的准确性：系统回顾和荟萃分析。

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-06-01 Epub Date: 2026-05-28 DOI: 10.1080/14737159.2026.2680033

Hasmat Ali, Rezhat Abbas, Aadithya B Urs, Priya Kumar, Jeyaseelan Augustine

{"title":"Diagnostic accuracy of fine-needle aspiration cytology in salivary gland neoplasms: a systematic review and meta-analysis.","authors":"Hasmat Ali, Rezhat Abbas, Aadithya B Urs, Priya Kumar, Jeyaseelan Augustine","doi":"10.1080/14737159.2026.2680033","DOIUrl":"10.1080/14737159.2026.2680033","url":null,"abstract":"Introduction: Fine-needle aspiration cytology is a widely used minimally invasive tool for salivary gland lesions, though diagnostic challenges arise due to overlapping features between benign and malignant tumors. This systematic review and meta-analysis evaluate its diagnostic performance in salivary gland neoplasms.Methods: A comprehensive literature search was conducted in PubMed/MEDLINE, Embase, Scopus, and Web of Science. Studies reporting sensitivity, specificity, or sufficient data to construct 2 × 2 tables were included. Data extraction was performed independently by two reviewers, and study quality was assessed using the QUADAS-2 tool. Diagnostic accuracy was pooled using a bivariate random-effects model, and summary receiver operating characteristic curves were generated. Publication bias was evaluated using Deeks' funnel plot.Results: A total of 56 studies were included, of which 32 were eligible for meta-analysis. The pooled sensitivity of FNAC was 0.79 (95% CI: 0.75-0.83), and specificity was 0.94 (95% CI: 0.93-0.96). The summary analysis demonstrated good discriminative ability with an area under the curve of 0.89. No significant publication bias was detected.Conclusions: FNAC demonstrates high diagnostic accuracy, with high specificity and moderate sensitivity, supporting its role as a reliable first-line diagnostic tool in salivary gland neoplasms.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"523-535"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148014102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human papillomavirus viral load as promising surrogate biomarker of cervical cancer risk and clinical outcome. 人乳头瘤病毒载量作为宫颈癌风险和临床结果的替代生物标志物。

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-06-01 Epub Date: 2026-05-31 DOI: 10.1080/14737159.2026.2675388

Ralph-Sydney Mboumba Bouassa, Jonathan Muwonga Tukisadila, Hugues Loemba, Laurent Bélec

{"title":"Human papillomavirus viral load as promising surrogate biomarker of cervical cancer risk and clinical outcome.","authors":"Ralph-Sydney Mboumba Bouassa, Jonathan Muwonga Tukisadila, Hugues Loemba, Laurent Bélec","doi":"10.1080/14737159.2026.2675388","DOIUrl":"10.1080/14737159.2026.2675388","url":null,"abstract":"Introduction: Persistent high-risk human papillomavirus (HR-HPV) causes cervical precancerous lesions and cancer. While molecular HPV DNA testing offers superior sensitivity over cytology as a primary screening method, its limited specificity leads to unnecessary follow-up procedures. Therefore, identifying surrogate biomarkers to distinguish transient infections from clinically relevant, persistent ones is essential for improving risk stratification. A comprehensive literature search across PubMed/MEDLINE, Embase, Scopus, and Web of Science databases up to December 2025 identified studies evaluating HR-HPV viral load in cervical lesion progression.Areas covered: Oncogenic HPV viral load, the quantity of HPV genomes in a sample, is a promising biomarker. Levels correlated positively with HR-HPV persistence, increasing the risk of high-grade lesions and invasive cervical cancer. Furthermore, quantification provides prognostic information regarding disease severity, therapeutic response, and post-treatment recurrence.Expert opinion: Recent standardization and validation of multiplex real-time PCR techniques supports integrating HPV viral load into clinical pratice. Incorporating viral load assessment into screening and management algorithms could significantly enhance diagnostic precision, enable personalized follow-up, and guide therapeutic decisions for women with HR-HPV-associated cervical disease. Refining these protocols will ultimately minimize over-treatment while ensuring rigorous monitoring for high-risk patients.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"501-522"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147940725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predicting 28-day all-cause mortality in critically ill ischemic stroke patients using white blood cell-to-hemoglobin ratio and dual-feature selection machine learning models. 利用白细胞-血红蛋白比和双特征选择机器学习模型预测危重缺血性脑卒中患者28天全因死亡率

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-06-01 Epub Date: 2026-05-19 DOI: 10.1080/14737159.2026.2673538

Hailong Yu, Aipeng Hu, Xiaoyun Huang, Luhang Tao, Jing Hang, Xin Chen, Lulu Zhou, Ying Chen, Tianwei Wang, Yuping Li, Jun Shao

{"title":"Predicting 28-day all-cause mortality in critically ill ischemic stroke patients using white blood cell-to-hemoglobin ratio and dual-feature selection machine learning models.","authors":"Hailong Yu, Aipeng Hu, Xiaoyun Huang, Luhang Tao, Jing Hang, Xin Chen, Lulu Zhou, Ying Chen, Tianwei Wang, Yuping Li, Jun Shao","doi":"10.1080/14737159.2026.2673538","DOIUrl":"10.1080/14737159.2026.2673538","url":null,"abstract":"Background: The white blood cell-to-hemoglobin ratio (WHR) is a composite biomarker of inflammation and nutrition, but its prognostic role in critically ill ischemic stroke (IS) patients is unclear.Methods: A cohort of 3,112 patients from MIMIC-IV was analyzed. WHR was calculated from first 24-hour ICU lab values. Its association with 28-day all-cause mortality(ACM) was assessed via survival analysis, Cox regression, restricted cubic splines (RCS), and subgroup analysis. Machine learning (ML) models were developed and evaluated using Receiver Operating Characteristic curve(AUC), calibration, and decision curve analysis.Results: Mortality differed significantly across WHR quartiles (Log-rank p < 0.0001). A higher WHR was independently associated with increased 28-day ACM (adjusted HR per SD = 1.42; 95% CI: 1.22-1.65, p < 0.001), showing a near-linear dose-response. WHR (AUC = 0.644) outperformed its components (white blood cells, hemoglobin). The association was stronger in non-ventilated patients (interaction p = 0.003). Among ML models, the Gradient Boosting Machine (GBM) performed best (test-set AUC = 0.814) and WHR was a key predictive feature.Conclusion: WHR is an independent predictor of short-term mortality in critically ill IS patients. Integrating WHR into ML models like GBM improves risk stratification, offering a valuable tool for clinical prognosis.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"537-546"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147867196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fusion genes in precision oncology: prostate cancer as a diagnostic case study. 融合基因在精准肿瘤学中的应用：前列腺癌诊断案例研究。

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-05-01 Epub Date: 2026-05-13 DOI: 10.1080/14737159.2026.2669277

Rebecca A Morgan, Gary Hardiman

{"title":"Fusion genes in precision oncology: prostate cancer as a diagnostic case study.","authors":"Rebecca A Morgan, Gary Hardiman","doi":"10.1080/14737159.2026.2669277","DOIUrl":"10.1080/14737159.2026.2669277","url":null,"abstract":"Introduction: Fusion genes represent one of the most specific molecular alterations in human cancer and have long served as important diagnostic and therapeutic biomarkers. Advances in next-generation sequencing have driven a rapid expansion in fusion gene discovery. Clinical translation has lagged however, particularly in solid tumors. This review critically examines the role of fusion genes in molecular diagnostics, focusing on opportunities, limitations and clinical implementation.Areas covered: We summarize the biological mechanisms underlying fusion gene formation as they influence diagnostic detection and interpretation. Current technologies for fusion detection in clinical practice are evaluated and major diagnostic pitfalls discussed. Prostate cancer is presented as a diagnostic case study to illustrate both the promise and limitations of fusion gene-based biomarkers.Expert opinion: Despite their biological appeal and tumor specificity, fusion genes remain underutilized in routine diagnostics due to interpretive complexity and limited clinical validation. In our view, fusion genes are most likely to deliver sustained diagnostic value when incorporated into targeted, standardized and context-aware diagnostic frameworks rather than pursued as isolated biomarkers. Over the next five years, fusion gene diagnostics are expected to become more selective, integrative and clinically disciplined, with emphasis shifting from discovery toward validated clinical utility.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"379-393"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147867175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liquid biopsy for biliary tract cancer: available evidence and future research directions. 胆道癌液体活检：现有证据及未来研究方向。

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-05-01 Epub Date: 2026-05-08 DOI: 10.1080/14737159.2026.2670701

Enes Erul, Angela Dalia Ricci, Mario Della Mura, Gerardo Cazzato, Raffaella Massafra, Pınar Kubilay Tolunay, Yüksel Ürün, Alessandro Rizzo

{"title":"Liquid biopsy for biliary tract cancer: available evidence and future research directions.","authors":"Enes Erul, Angela Dalia Ricci, Mario Della Mura, Gerardo Cazzato, Raffaella Massafra, Pınar Kubilay Tolunay, Yüksel Ürün, Alessandro Rizzo","doi":"10.1080/14737159.2026.2670701","DOIUrl":"10.1080/14737159.2026.2670701","url":null,"abstract":"Introduction: Biliary tract cancers (BTCs) are molecularly heterogeneous, and early genomic profiling is becoming increasingly important for treatment decisions. Because tissue sampling is often limited or inadequate, there is a clear need for minimally invasive biomarkers that can support treatment selection and longitudinal disease assessment.Areas covered: This narrative review summarizes current and emerging liquid-biopsy (LB) applications in BTC, with a primary focus on plasma circulating tumor DNA (ctDNA). The evidence base was assembled through targeted searches of PubMed/MEDLINE and Embase up to 1 February 2026, supported by selective ClinicalTrials.gov searches for ongoing biomarker-driven studies. We discuss ctDNA-based molecular profiling for actionable alterations, its prognostic role including minimal residual disease assessment, and its use in serial monitoring of treatment response and acquired resistance. We also consider how LB may support clinical-trial enrichment and biomarker-guided endpoints, and briefly review complementary approaches using bile and other analytes, while highlighting current evidence gaps.Expert opinion: In BTC, ctDNA is best viewed as a complement to tissue-based profiling, especially when tissue is inadequate or when rapid genotyping is needed. Its broader clinical impact will depend on assay standardization, clearer interpretation frameworks for low-shedding disease, and prospective studies showing that ctDNA-guided decisions improve patient outcomes.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"423-437"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative review of diagnostic techniques for DNA methylation analysis. DNA甲基化分析诊断技术的比较综述。

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-05-01 Epub Date: 2026-05-24 DOI: 10.1080/14737159.2026.2669271

Luiza Loureiro de Araújo, Hiago Azevedo Cintra, Letícia Lopes Cabral Guimarães Fonseca, Leonardo Lima de Faria, Danielle Nascimento Rocha, Marcio da Costa Cipitelli, Cibele Xavier Cenciani, Júlia Alves Correa Gonçalves, Leonardo Henrique Ferreira Gomes, Letícia da Cunha Guida

{"title":"Comparative review of diagnostic techniques for DNA methylation analysis.","authors":"Luiza Loureiro de Araújo, Hiago Azevedo Cintra, Letícia Lopes Cabral Guimarães Fonseca, Leonardo Lima de Faria, Danielle Nascimento Rocha, Marcio da Costa Cipitelli, Cibele Xavier Cenciani, Júlia Alves Correa Gonçalves, Leonardo Henrique Ferreira Gomes, Letícia da Cunha Guida","doi":"10.1080/14737159.2026.2669271","DOIUrl":"10.1080/14737159.2026.2669271","url":null,"abstract":"Introduction: DNA methylation is a crucial epigenetic modification regulating gene expression, essential for embryonic development, cellular differentiation, and disease susceptibility. Aberrant methylation is associated with cancer, neurodegenerative and cardiovascular diseases, and imprinting disorders, highlighting the need for reliable biomarkers.Areas covered: This review summarizes six widely used DNA methylation analysis techniques: Methylation-Specific PCR (MSP), quantitative (qMSP), Methylation-Specific MLPA (MS- MLPA), Methylation-Sensitive High-Resolution Melting (MS-HRM), pyrosequencing, MassARRAY, and digital droplet PCR (ddPCR). Their principles, clinical applications, strengths, and limitations are discussed, focusing on sensitivity, specificity, cost, and laboratory requirements. MS-HRM is cost-effective and highly sensitive for clinical screening; MS- MLPA enables multiplexed detection of methylation and copy number changes; pyrosequencing and MassARRAY offer quantitative CpG-level resolution; and ddPCR allows absolute quantification in low-DNA or mosaic samples.Expert opinion: These techniques offer important advances for epigenetic diagnostics, yet further validation, protocol standardization, and simplification are needed for routine clinical use. Choosing the optimal method depends on study goals, sample type, and clinical needs. Integrating these approaches into standardized workflows can enhance early disease detection, therapeutic monitoring, and personalized epigenetic interventions, supporting precision medicine.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"439-451"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of cell free DNA methylation as a biomarker to differentiate different liver diseases. 细胞游离DNA甲基化作为区分不同肝脏疾病的生物标志物的评估。

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-05-01 Epub Date: 2026-05-04 DOI: 10.1080/14737159.2026.2669647

Jing Zuo, Xin-Hua Guo, Hang-Yu Ma, Jie-Ru Yang, Yu-Chen Fan

{"title":"Evaluation of cell free DNA methylation as a biomarker to differentiate different liver diseases.","authors":"Jing Zuo, Xin-Hua Guo, Hang-Yu Ma, Jie-Ru Yang, Yu-Chen Fan","doi":"10.1080/14737159.2026.2669647","DOIUrl":"10.1080/14737159.2026.2669647","url":null,"abstract":"Introduction: A major challenge in many liver diseases is the lack of highly sensitive, specific, and minimally invasive biomarkers. Cell-free DNA (cfDNA) methylation compensates for the limitations of existing biomarkers and exhibits substantial clinical application potential in a variety of liver diseases, notably hepatocellular carcinoma (HCC). A systematic literature search was conducted in the PubMed, Web of Science Core Collection, and Cochrane Library databases from 1 January 2000, to 31 December 2025.Areas covered: This article systematically explores the value of cfDNA methylation as a biomarker in diverse liver diseases, covering metabolic-associated fatty liver disease, hepatitis B virus-related liver disease, autoimmune liver diseases, cholestatic liver disease, graft injury after liver transplantation, acute-on-chronic liver failure, and HCC.Expert opinion: cfDNA methylation is a promising biomarker. In various liver diseases, particularly HCC, its diagnostic efficacy not only outperforms some traditional biomarkers but also complements others. Coupled with its minimally invasive nature, this supports personalized treatment strategies and long-term disease management. However, current research lacks standardized protocols. Future efforts should therefore focus on establishing unified standards for technical procedures, data analysis, and clinical interpretation to accelerate its translation from basic research to clinical application.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"409-421"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147812435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical utility of novel point-of-care Amnioquick card tests for the assessment of pre-labor rupture of fetal membranes: a narrative review. 临床实用新型点护理羊膜快速卡测试评估产前胎膜破裂。

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-05-01 Epub Date: 2026-05-16 DOI: 10.1080/14737159.2026.2671357

George Uchenna Eleje, Emmanuel Chukwubuikem Egwuatu, Chichi Ukoha, Lydia Ijeoma Eleje, Akaninyene Eseme Ubom, Ahizechukwu Chigoziem Eke

{"title":"Clinical utility of novel point-of-care Amnioquick card tests for the assessment of pre-labor rupture of fetal membranes: a narrative review.","authors":"George Uchenna Eleje, Emmanuel Chukwubuikem Egwuatu, Chichi Ukoha, Lydia Ijeoma Eleje, Akaninyene Eseme Ubom, Ahizechukwu Chigoziem Eke","doi":"10.1080/14737159.2026.2671357","DOIUrl":"10.1080/14737159.2026.2671357","url":null,"abstract":"Introduction: Pre-labor rupture of membranes (PROM) remains a major contributor to adverse maternal and neonatal outcomes, particularly in settings where diagnostic uncertainty delays appropriate intervention. Novel point-of-care biochemical assays, including the Amnioquick card test, have emerged to address the limitations of conventional bedside methods in PROM diagnosis.Areas covered: This narrative review synthesizes evidence from nine peer-reviewed studies encompassing 1,255 participants to evaluate the diagnostic accuracy, clinical applicability, and limitations of the Amnioquick assays. Reported sensitivity ranged from 93.3% to 100%, specificity (86.4%-100%), positive predictive value (87.3%-100%), negative predictive value (73.7%-100%), and overall accuracy from 90.0% to 99.1%. These results demonstrate robust diagnostic performance across diverse clinical and geographic contexts, with consistent findings even in equivocal samples.Expert opinion: Amnioquick provides rapid, reliable confirmation of PROM at bedside using dual markers insulin-like growth factor binding protein-1 (IGFBP-1) and alpha-fetoprotein (AFP), improving accuracy over single marker or pH tests and reducing unnecessary interventions. Its simplicity, minimal infrastructure needs, and quick results make it suitable for low and middle-income settings. Barriers such as cost, limited multicentre validation, and reduced reliability in contaminated samples remain. Future goals include triton-free formulation, integration with digital readers and electronic decision tools, and large multicentre outcome-linked evaluations.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"395-407"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blood-based biomarkers for Alzheimer's disease. 'Treat the test, not the patient?'; are we ready to defy Osler? 阿尔茨海默病的血液生物标志物。“治疗测试，而不是病人？”我们准备好反抗奥斯勒了吗？

IF 3.6 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-05-01 Epub Date: 2026-05-10 DOI: 10.1080/14737159.2026.2669646

Paul Connon, Mary Clare McKenna, Sandra E Black, Mario Masellis

引用次数: 0